Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library

BPC-157 vs PEA (palmitoylethanolamide)

BPC-157 and PEA are both discussed for pain and inflammation, but PEA is not a peptide: it is palmitoylethanolamide, the naturally occurring amide of palmitic acid and ethanolamine 7. BPC-157 is a synthetic 15-amino-acid peptide whose human evidence consists of three small uncontrolled reports 2,5. PEA has been tested in dozens of randomized controlled trials as a supplement, mostly in pain and neuropsychiatric conditions 9,10. Neither has an FDA drug approval as of October 2026 1,14.

Unbranded reference vial illustrating BPC-157; not an actual product
BPC-157
Not approved — research use only
Unbranded reference vial illustrating PEA; not an actual product
PEA
Not approved — research use only

Side by side

FieldBPC-157PEA
ClassSynthetic pentadecapeptide (15 amino acids) 5Endogenous fatty acid amide (endocannabinoid-like lipid mediator); not a peptide 7,10
Origin and structurePartial sequence of 'body protection compound' isolated from human gastric juice 5Amide of palmitic acid and ethanolamine, produced in mammalian cells and tissues and present in plant and animal foods 7,8
Proposed mechanismPreclinical work suggests growth hormone receptor up-regulation, angiogenesis pathways and reduced inflammatory cytokines 1; FAK-paxillin activation in rat tendon fibroblasts 5Activates the nuclear receptor PPAR-alpha; anti-inflammatory effects were absent in PPAR-alpha-deficient mice 7
Half-lifeUnder 30 minutes, from rat and dog pharmacokinetic work cited in a systematic review; no human data 1Not located in the sources reviewed; a rat study compared plasma exposure across formulations without reporting a half-life in its abstract 12
Highest human trial phasePhase 1 registration in healthy volunteers, status unknown, no results posted 6Phase 2 (ultramicronized PEA in hospitalised COVID-19, terminated) 13; 47 randomized trials identified in a 2025 systematic review 10
FDA statusNot FDA-approved 1; listed among bulk substances that may present significant safety risks (nomination withdrawn), as of 22 April 2026 15No Drugs@FDA application record located (searched 24 October 2026) 14; not on the FDA's significant-safety-risk compounding page 15
Published human outcomesThree small uncontrolled reports (30 people in total) described symptom improvement; certainty rated very low 2,3,4A meta-analysis of 11 double-blind RCTs (774 patients) found lower pain scores versus comparators 9; a crossover trial found no effect on recovery from exercise-induced muscle damage 11
Safety signalsNo clinical safety data found in one systematic review 1; FDA cites immunogenicity and impurity concerns and limited safety information 15No major side effects were attributed to PEA in the 11 meta-analysed trials 9
WADA statusNamed under S0 (non-approved substances); prohibited at all times (2026 List) 16Not named on the 2026 List 16
Who funded the evidenceCell studies from Chang Gung University 5; human reports from private clinics 3,4; the phase 1 registration was sponsored by PharmaCotherapia 6Mixed: academic trials and reviews 9,11, with some work co-authored or sponsored by PEA manufacturers or developers (Epitech Group, Bio-gen Extracts, Quantum Biopharma) 8,12,13

BPC-157: what the data says

A systematic review of 36 BPC-157 studies found 35 preclinical studies and one clinical study 1. In rat tendon-fibroblast cultures (cell data), BPC-157 increased explant outgrowth, survival under oxidative stress and cell migration 5. In animal injury models, the review reports improved functional, structural and biomechanical outcomes in muscle, tendon, ligament and bone (animal data only) 1.

  • Human data are limited to three small uncontrolled reports: a telephone chart-review survey of knee pain, a 12-woman interstitial cystitis pilot and a 2-person intravenous safety pilot 2,3,4.
  • A 2026 systematic review rated the certainty of this human evidence as very low 2.

PEA: what the data says

PEA's anti-inflammatory activity in mice depended on PPAR-alpha: it reduced paw and ear oedema in wild-type mice but not in PPAR-alpha-deficient mice (animal data) 7. In humans it has been studied mainly as an oral supplement, including micronized and ultramicronized formulations 8,10.

  • A 2023 meta-analysis of 11 double-blind randomized trials in chronic pain (774 patients) reported lower pain intensity with PEA than comparators 9.
  • A 2025 systematic review identified 47 randomized trials across neuropsychiatric, neurological, somatic and visceral conditions 10.
  • In an 11-man randomized crossover trial (humans), PEA did not change soreness, strength, jump performance or muscle-damage markers after eccentric exercise 11.
  • A phase 2 trial of ultramicronized PEA in hospitalised COVID-19 patients was terminated after enrolling 53 participants, with no results posted 13.

Key research differences

  • Chemistry: BPC-157 is a 15-amino-acid peptide 5, whereas PEA is a fatty acid amide and not a peptide 7.
  • Human evidence: PEA has dozens of randomized controlled trials 10, while BPC-157 has three small uncontrolled reports rated very low certainty 2.
  • Mechanism: PEA's anti-inflammatory action in mice required PPAR-alpha 7; BPC-157 has several proposed pathways without a single identified receptor 1.
  • Anti-doping: BPC-157 is named under WADA S0, while PEA is not named on the 2026 List 16.
  • FDA compounding concerns: BPC-157 appears on the FDA's significant-safety-risk compounding page; PEA does not 15.

Where the evidence is limited

No study has compared BPC-157 and PEA directly. They belong to different chemical classes, are studied by different routes and in different conditions, and their evidence bases differ in size and design: mostly animal data for BPC-157 versus randomized human trials for PEA 1,10. PEA trials vary in formulation and population, and some were run or co-authored by manufacturers 8,13. A pooled pain result for PEA does not imply anything about BPC-157, and vice versa 2,9.

Frequently asked questions

Is PEA a peptide?
No. PEA (palmitoylethanolamide) is the amide of palmitic acid and ethanolamine, a lipid signalling molecule 7. BPC-157 is a 15-amino-acid peptide 5.
Which has more human research, BPC-157 or PEA?
PEA: a 2025 systematic review identified 47 randomized controlled trials 10. BPC-157 has three small uncontrolled human reports 2.
Can BPC-157 and PEA be compared directly?
No head-to-head study was located, and their evidence comes from different models and conditions, so a direct comparison is not supported 1,10.
Are BPC-157 and PEA banned in sport?
WADA's 2026 List names BPC-157 under S0 (non-approved substances); PEA is not named 16.

References

  1. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review HSS Journal. 2025
  2. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety Acta Orthopaedica Belgica. 2026
  3. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain Alternative Therapies in Health and Medicine. 2021
  4. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study Alternative Therapies in Health and Medicine. 2024
  5. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration Journal of Applied Physiology. 2011
  6. PCO-02 - Safety and Pharmacokinetics Trial (NCT02637284) ClinicalTrials.gov. 2015
  7. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide Molecular Pharmacology. 2005
  8. The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations British Journal of Pharmacology. 2017
  9. Palmitoylethanolamide in the Treatment of Chronic Pain: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials Nutrients. 2023
  10. Palmitoylethanolamide supplementation for human health: A state-of-the-art systematic review of Randomized Controlled Trials in patient populations Brain, Behavior, & Immunity - Health. 2025
  11. Palmitoylethanolamide Does Not Affect Recovery from Exercise-Induced Muscle Damage in Healthy Males Medicine and Science in Sports and Exercise. 2024
  12. Pharmacokinetics of micronized and water dispersible palmitoylethanolamide in comparison with standard palmitoylethanolamide following single oral administration in male Sprague-Dawley rats Indian Journal of Pharmacology. 2025
  13. Ultramicronized Palmitoylethanolamide (PEA) Treatment in Hospitalized Participants With COVID-19 (NCT04619706) ClinicalTrials.gov. 2022
  14. Drugs@FDA (openFDA) query for active ingredient palmitoylethanolamide: no matches FDA openFDA. 2026
  15. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 04/22/2026) FDA (Human Drug Compounding). 2026
  16. Prohibited List 2026 (in force 1 January 2026) World Anti-Doping Agency. 2026

For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement. This page compares published research and is not medical advice or a recommendation.